Joseph Pantginis News
-
Peregrine Pharmaceuticals Inc. plunged the most ever after the biotechnology company said the survival rates from its lung cancer study reported earlier this month were unreliable.
-
Regeneron Pharmaceuticals Inc. reported a successful study result in its new drug for treating gout, the first of three new treatments that may generate at least $2 billion a year in revenue.
-
Pfizer Inc. and Celldex Therapeutics Inc. ’s said 70 percent of patients getting their experimental brain tumor vaccine were alive without their cancer worsening about eight months after diagnosis, a study found.
-
Dendreon Corp. won approval for its only product, the prostate cancer vaccine Provenge, concluding a three-year battle with U.S. regulators to introduce the first therapy to train the body’s immune system to destroy tumors.
-
Micromet Inc. , a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals.
-
Dendreon Corp., maker of the prostate cancer drug Provenge, fell 7 percent after Johnson & Johnson said its rival product, Zytiga, performed better than a placebo in a trial.
-
Dendreon Corp., maker of the prostate-cancer drug Provenge, rose the most in almost three years after saying fourth-quarter revenue for its only product more than tripled from a year earlier.
-
Pfizer Inc . is pulling out of an agreement with Celldex Therapeutics Inc. to fund the development of an experimental brain tumor vaccine. Celldex shares fell the most in almost two years.
-
Regeneron Pharmaceuticals Inc.’s Arcalyst cut by 80 percent the recurrence of painful flare-ups of gout in a study. The drug didn’t work to reduce pain once the condition began, a second trial found.
-
Pharmacyclics Inc., the cancer-drug maker that announced a deal with Johnson & Johnson yesterday, fell the most in 19 months after RBC Capital Markets said the transaction means it is unlikely to be acquired.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page